Lilly expects orforglipron obesity results in third quarter
By Deena Beasley
(Reuters) -Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and the company aims to announce in the third quarter trial results for the drug in overweight and obese people without diabetes.
Lilly expects to submit the non-diabetes Phase 3 data to global regulatory agencies by the end of the year, said Ken Custer, head of cardiometabolic health at the company. The U.S. Food and Drug Administration typically makes new drug approval decisions 10 months after a manufacturer's submission.
Lilly said it plans to file for regulatory approvals for orforglipron as a diabetes treatment in 2026.
Full results of the diabetes trial were presented at the annual meeting of the American Diabetes Association in Chicago.
The Phase 3 study showed that type 2 diabetes patients taking the highest dose of daily orforglipron lost nearly 8% of their body weight over 40 weeks. That compares favorably with Novo Nordisk's injected drug Ozempic, for which trials showed that diabetic patients on the highest dose lost roughly 6% of their body weight.
Lilly's pill, which can be taken without food or water, lowered blood sugar levels by an average of 1.3% to 1.6% across doses.
The company said the most frequently reported side effects were gastrointestinal and similar to other GLP-1 drugs, including diarrhea and vomiting.
Custer said Lilly's goal in its non-diabetes trials is to achieve weight loss consistent with GLP-1 drugs that are currently available. Ozempic was shown in trials to lead to weight loss of 15% for people without diabetes over 68 weeks.
He said orforglipron, which has a simpler production process than injected GLP-1 drugs such as Ozempic or Lilly's Zepbound and does not require cold storage, could mean wider global access to weight-loss drugs.
"This is the type of molecule that is going to allow us to reach the broader globe," Custer said.
The executive declined to comment on pricing plans for orforglipron.
(Reporting By Deena BeasleyEditing by Rod Nickel)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
6 Things Women over 50 Should Do Every Night Before Bed, According to Dietitians
Reviewed by Dietitian Karen Ansel, M.S., RDNAfter age 50, women undergo many physical and hormonal changes. They may experience hot flashes, difficulty sleeping and feelings of stress. The following bedtime habits can help them de-stress, sleep better and have more 50 is an incredible milestone. You're wiser, more confident and unapologetically yourself. But let's be honest. Our bodies and minds don't exactly operate like they did in our 20s. From fluctuating hormones to the occasional creaking bones and aching joints, it's clear that self-care needs to take center stage. And what better time to give yourself some TLC than right before bed? After all, your evening routine can set the tone for quality sleep, mental clarity and a healthier tomorrow. To get you started, we reached out to registered dietitians for simple yet effective ways women over 50 can optimize their nights. These aren't complicated rituals or time-consuming chores. They are just six practical, doable habits to help you wind down your day while doing something good for your body and mind at the same time. If you enjoy an alcohol-containing drink in the evening, consider swapping it for a booze-free mocktail or a glass of alcohol-free wine or beer. 'Most women over age 50 complain of insomnia and sleep disturbances due to perimenopause and menopause,' says Melissa Azzaro, RDN, LD. 'Symptoms like hot flashes and night sweats can keep women up, and other hormone imbalances can make it difficult to get a full night of quality sleep.' This is why she recommends that women over 50 cut out alcohol before bed. 'While you may feel that it helps you fall asleep faster, it results in more interrupted, less restful sleep,' she says. Research agrees, linking higher alcohol consumption to shorter, less restorative sleep and even snoring. 'After 50, women lose muscle mass more rapidly due to hormonal shifts, specifically [due to] a decline in estrogen levels during menopause, which affects bone density and muscle strength,' says Jamie Lee McIntyre, M.S., RDN. 'Protein before bed—such as Greek yogurt, cottage cheese or a plant-based protein smoothie—[has been shown to] support overnight muscle repair and synthesis, especially when paired with resistance exercise.' For example, one study found that men who ate protein after working out in the evening had higher rates of muscle building and repair than those who performed evening exercise without consuming protein. While we can't say for sure that the same would be true for women, a healthy, protein-rich bedtime snack is worth a try. Now that you've had your snack, it's time to brush those teeth—even if you're tired and can't motivate! Brushing before bed is important for everyone. But it becomes even more critical as you enter your 50s as oral health becomes increasingly tied to your overall health as you age. Problems like dry mouth, tooth loss, cavities, gum disease and oral cancer are more common in older people and can affect more than just their teeth. They can also lead to issues like poor nutrition and lower quality of life and can even worsen conditions like heart disease or diabetes. Plus, when your teeth are in good shape, it's easier—and more enjoyable—to eat healthy foods like fruits and veggies! The simple act of having a glass of water by your bedside could be one of the most underrated habits for women who are over age 50. 'Even if you don't wake up in the night, night sweats can dehydrate you during sleep, so you are most likely waking up somewhat dehydrated,' explains Frances Largeman-Roth, RDN. 'Having the water right there next to you helps you get a jump on hydration for the day, which helps you feel your best.' And if hot flashes are an issue, sipping cold water before you hit the hay might help cool things off, according to the National Institutes of Health. Magnesium plays a crucial role in muscle relaxation, maintaining a healthy nervous system and regulating sleep. Yet, as we age, we may not absorb this mineral as efficiently as we did when we were younger. And many of us don't consume enough magnesium to meet our needs. Enter magnesium glycinate. This highly absorbable form of magnesium is readily taken up by the body for more restful sleep and overall relaxation at the end of the day. Beyond sleep, this supplement may aid in maintaining strong bones, as magnesium is essential for calcium absorption and bone mineralization. Prioritizing bone health becomes increasingly important after age 50 to reduce the risk of osteoporosis and maintain overall mobility. Research shows that higher magnesium intake is linked to better bone density in the hip and femoral neck, which are key areas for mobility and strength. Diaphragmatic breathing, or deep belly breathing, is a simple way to calm your body and mind. 'This slow, intentional breathing—inhale through the nose with a deep belly expansion followed by a slow exhale— can calm the nervous system and may promote better sleep,' says Brittany Scanniello, RDN. It may also support your long-term heart health. How so? Stress is linked to an increased risk of heart disease, which is a leading cause of death for older women. Promising research has shown that diaphragmatic breathing can reduce stress levels by improving blood pressure and respiratory rate and lowering the stress hormone cortisol. While more research is needed, taking a few deep belly breaths before turning in could be an easy, low-cost way to ease your stress. Your nighttime habits can be an impactful way to prioritize self-care and support your body through the changes that happen after age 50. Whether you recently turned 50 or have already passed this milestone, dietitians recommend making the most of your evenings by swapping out alcohol for mocktails, eating a protein-rich bedtime snack and staying hydrated. They also recommend taking a magnesium glycinate supplement and doing some deep-breathing exercises to help you wind down and prepare for restorative sleep. And don't forget to brush those teeth! As you age, your dental health impacts multiple aspects of your overall health. Remember, small changes can lead to big results over time. By choosing to nurture your body and mind in these practical ways, you're setting the foundation for healthier days and more peaceful nights. Read the original article on EATINGWELL
Yahoo
an hour ago
- Yahoo
Famous drama actor battling ALS says he has lost use of his arm
Former 'Grey's Anatomy' star Eric Dane is dealing with some major side affects amid his ongoing battle with ALS. 'I have one functioning arm,' the 52-year-old said in an interview with Diane Sawyer that aired Monday on "Good Morning America." 'My right side [has] completely stopped working,' Dane said. While the actor still has mobility of his left arm, he added that he is slowly starting to lose function of it as well. 'It's going,' Dane said. 'I feel like maybe a couple, few more months and I won't have my left hand either.' The actor is walking fine right now, but is already thinking about how the disease will impact his legs. 'I wake up every day and I'm immediately reminded that this is happening,' he told Sawyer. 'It's not a dream.' ALS, otherwise referred to as Lou Gehrig's disease, impacts the nervous system. The non-curable disease affects nerve cells in the brain and spinal cord, eventually causing paralysis and restricting essential bodily functions such as speaking, eating and breathing, according to the Mayo Clinic. The CDC estimates roughly 33,000 people are fighting ALS in the U.S. Dane called his battle with ALS 'sobering.' His journey started when he first started experiencing weakness in his right hand more than a year ago. The actor didn't think much of it at first, until it worsened over the course of a few weeks. Dane then went from hand specialist to hand specialist, then neurologist to neurologist. After nine months of being in the dark, Dane was finally diagnosed with ALS in April. The actor, who shares two teenager daughters with actress Rebecca Gayhart, said he is focused on his family and work. 'All I want to do is spend time with my family and work a little bit if I can,' Dane said. 'I don't think this is the end of my story. I just don't feel like, in my heart, I don't feel like this is the end of me.' Dane appeared in television programs in the 1990s and 2000s, including ' Children,' 'Roseanne' and 'Charmed.' He rose to fame when he was cast as Dr. Mark Sloan (a.k.a Dr. McSteamy) on 'Grey's Anatomy' in 2006. The actor stayed on the show until 2012, appearing in more than 130 episodes and receiving several accolades. Dane landed his first leading film in role in the 2006 German-made feature, 'Open Water 2: Adrift.' He was also a co-star in 'Marley & Me' (2008) and 'Valentine's Day' (2010) as well as appeared in 'X-Men: The Last Stand.' The actor has most recently appeared as Captain Tom Chandler in 'The Last Ship' and as Cal Jacobs in HBO's 'Euphoria.' Actor 'addicted' to Karen Read trial says he invited her to Mass. concert 'Bachelor' winner from Mass. splits from fiancé nearly 3 months after finale Emmy-nominated actor from 'Scarface,' 'Ghostbusters II' dies at 87 Legendary songwriter, co-founder of iconic '60s band dies at 82 Doechii calls out Trump's 'ruthless attacks' to stop Los Angeles protests Read the original article on MassLive.
Yahoo
an hour ago
- Yahoo
Semaglutide Increases Walking Capacity in Patients with Peripheral Artery Disease and Type 2 Diabetes
Common obesity drug reduced the risk of disease progression by 54% CHICAGO, June 21, 2025 /PRNewswire/ -- Today, a new analysis demonstrates the vascular benefits of semaglutide in patients with peripheral artery disease (PAD) and type 2 diabetes, including improvement in symptoms, quality of life, and disease progression in patients. An analysis of the STRIDE trial was presented as a late-breaking symposium at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago and simultaneously published in Diabetes Care®. PAD is a serious condition impacting 230 million individuals globally and up to 30% of people with diabetes. PAD narrows arteries and reduces blood flow to the legs, causing marked disability, affecting quality of life, and putting people at increased risk of severe complications including amputations and death. Treatment options are currently limited, and little advancements in PAD treatment have occurred for more than 25 years. The STRIDE trial is a phase 3, multinational, double-blind, randomized clinical trial conducted at 112 outpatient clinical trial sites in 20 countries in North America, Asia, and Europe. 792 patients aged 18 years and older with type 2 diabetes and PAD with intermittent claudication (a symptom of PAD that causes muscle pain or cramping in the legs during physical activity) and reduced ankle-brachial or toe-brachial index (indicators of restricted blood flow to the legs), were randomly assigned to receive either semaglutide (n=396) or placebo (n=396) over a 52-week period to assess the impact on walking capacity, symptoms, and quality of life. The median age was 68 years, and 195 (25%) participants were female and 597 (75%) were male. The sub-analysis builds on results previously published in The Lancet, demonstrating that semaglutide significantly improved walking outcomes in people with PAD and diabetes, enhanced quality of life, and reduced the risk of disease progression by 54%. At week 52, the estimated median ratio to baseline in maximum walking distance was 1.21 in the semaglutide group compared to 1.08 in the placebo group. Semaglutide was well tolerated, with no treatment-related deaths and a low rate of serious adverse events (1%), consistent with its known safety profile. The analyses from STRIDE presented new and critical information on the benefits of semaglutide, which were observed independent of baseline levels of A1C, duration of diabetes, or intensity of diabetes. Furthermore, the benefits were seen across all BMI categories and regardless of the treatment with SGLT2 inhibitors. "These findings indicate that clinicians can now recognize semaglutide as a vascular protective medication, with benefits that extend beyond lowering weight or A1C," said Professor Subodh Verma, MD, PhD, FRCSC, FAHA, FCAHS, cardiovascular surgeon, University of Toronto, Toronto, Canada, and senior author of the STRIDE trial. "The totality of data now suggest that in people with diabetes, semaglutide favorably affects the pipes [atherosclerosis], pump [heart failure], filter [kidney outcomes]. And, in patients with PAD, these new data provide robust evidence that semaglutide is a therapy to improve their function, quality of life, and progression of disease."The study authors indicate that further research is warranted to understand whether these benefits extend to individuals with PAD who do not have diabetes. Research presentation details:Dr. Verma will present the findings at the following symposium: Symposium: Diabetes and Peripheral Artery Disease—Evolving Role of GLP-1 RA and New Insights from the STRIDE Trial Presented on Saturday, June 21 at 1:30 p.m. CT About the ADA's Scientific SessionsThe ADA's 85th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in Chicago, IL, on June 20–23. Thousands of leading physicians, scientists, and health care professionals from around the world are expected to convene both in person and virtually to unveil cutting-edge research, treatment recommendations, and advances toward a cure for diabetes. Attendees will receive exclusive access to thousands of original research presentations and take part in provocative and engaging exchanges with leading diabetes experts. Join the Scientific Sessions conversation on social media using #ADASciSessions. About the American Diabetes AssociationThe American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to end diabetes and helping people thrive. This year, the ADA celebrates 85 years of driving discovery and research to prevent, manage, treat, and ultimately cure—and we're not stopping. There are 136 million Americans living with diabetes or prediabetes. Through advocacy, program development, and education, we're fighting for them all. To learn more or to get involved, visit us at or call 1-800-DIABETES (800-342-2383). Join us in the fight on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), and Instagram (@AmDiabetesAssn). To learn more about how we are advocating for everyone affected by diabetes, visit us on X (@AmDiabetesAssn). Media Contact: Mimi Carmody, MCarmody@ View original content to download multimedia: SOURCE American Diabetes Association Sign in to access your portfolio
